Investigational drug · Phase 2
INBRX-109
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Conventional Chondrosarcoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "INBRX-109"
First trial start
2021
Sep 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INBRX-109", any sponsor or status.
Conditions studied
As listed on its trial records.
- Conventional Chondrosarcoma
Largest trials
Live from ClinicalTrials.gov: studies naming "INBRX-109" as an intervention, largest first.
Inhibrx Biosciences, IncIndustry
NCT03715933 · 411 participants (planned) · Start Oct 8, 2018 · Primary completion Dec 2028
Drug: INBRX-109; Irinotecan and 7 more · For: Ewing Sarcoma; Colorectal Adenocarcinoma
Sites: Scottsdale, Arizona; Beverly Hills, California; Duarte, California · 37 sites in all
- Study of INBRX-109 in Conventional ChondrosarcomaPivotal-lookingActive, not recruiting
Inhibrx Biosciences, IncIndustry
NCT04950075 · 206 participants · Start Sep 23, 2021 · Primary completion Sep 30, 2025
Drug: INBRX-109; Placebo · For: Conventional Chondrosarcoma
Sites: Phoenix, Arizona; Beverly Hills, California; San Francisco, California · 68 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies.
Dedousis D, Gadra E, Van Galen J, et al. · Curr Treat Options Oncol 2025
- Advancing Systemic Therapy in Chondrosarcoma: New Horizons.
Li KHC, Gulia A, Duffaud F, et al. · Oncol Ther 2025
- Targeting Death Receptor 5 (DR5) for the imaging and treatment of primary bone and soft tissue tumors: an update of the literature.
Gamie Z, Krippner-Heidenreich A, Gerrand C, et al. · Front Mol Biosci 2024
- Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V, Chawla SP, Conley AP, et al. · Clin Cancer Res 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.